SARS-CoV-2 infection: efficacy of extensive vaccination of the healthcare workforce in a large Italian hospital

Main Article Content

Maurizio Coggiola
Giuseppe Clemente
Roberto Frammartino
Eugenio Grillo
Alessio Corradi
Michele Corezzi
Omar Kakaa
Ettore Paradisi
Alessandro Tuffanelli
Maria Carolina Alfonso Pensamiento
Alessandro Godono
Enrico Pira


mRNA vaccine, intra-hospital epidemic, prevention, biological risk, COVID-19


Background: A prospective observational study involved 13,787 Health Care Workers (HCWs) of a large hospital to assess the effectiveness of a SARS-CoV-2 mRNA vaccine. Methods: The daily incidence of infections was estimated from 1st October 2020 to 30th April 2021 and compared with that of the province of Turin (2.26 million). In the middle of this period, a mass vaccination began among HCW, and its effect was assessed. Results: In the first half-period, 1,163 positive HCWs were observed, the average daily incidence rate per 100,000 being 79.58 (± 15.58; 95% CI) compared to 38.54 (± 5.96; 95% CI) in the general population (p<0.001). The vaccination campaign immunized 9,843 HCWs; among them, the average daily incidence was 14.23 (± 2.73; 95% CI) compared to 34.2 (± 2.95; 95% CI) in the province (p<0.001). Among fully vaccinated HCW, 59 cases were observed, giving rise to an incidence of 6.3 (± 2.66; 95% CI) much lower than in the province (p<0.001). In the second half of the observation period, the RR for HCWs compared to the province dropped from 2.07 (1.96 – 2.18; 95% CI; p<0.001) to 0.5 (0.42 – 0.58; 95% CI; p<0.001) and to 0.17 (0.13 – 0.22; 95% CI; p<0.001) for unvaccinated and vaccinated HCWs, respectively. The RR of vaccinate HCW was 0.43 (0.31 – 0.58; 95% CI; p<0.001) compared to unvaccinated. In the second half of the observation period, unvaccinated HCWs had a RR of 0.21 (0.18 – 0.25; 95% CI; p<0.001) as compared to the first one. A linear regression model (R2 = 0.87) showed that every percent increase in vaccinated HCWs lowered daily incidence by 0.94 (0.86 – 1.02; IC 95%; p<0.001). Vaccinated HCWs had a RR of 0.09 (0.07 – 0.12; 95% CI; p<0.001) compared to unvaccinated HCWs, which led to estimated effectiveness of the two-dose vaccine of 91 % (± 3 %; CI 95%) similar to that reported by the manufacturer. 


Download data is not yet available.
Abstract 679 | PDF Downloads 307


1. World Health Organization. Coronavirus Disease (COVID-19) Situation Dashboard.; 2021. Accessed June 10, 2021.
2. World Health Organization. WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19 — 11 March 2020.; 2020. Accessed June 10, 2021.
3. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2021.; 2021. Accessed June 10, 2021.
4. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516-527. doi:10.1038/s41586-020-2798-3
5. Rego GNA, Nucci MP, Alves AH, et al. Current clinical trials protocols and the global effort for immunization against sars-cov-2. Vaccines. 2020;8(3):1-44. doi:10.3390/vaccines8030474
6. Hasan T, Beardsley J, Marais BJ, Nguyen TA, Fox GJ. The implementation of mass-vaccination against SARS-CoV-2: A systematic review of existing strategies and guidelines. Vaccines. 2021;9(4). doi:10.3390/vaccines9040326
7. WHO. World Health Organisation. WHO Issues Its First Emergency Use Validation for a COVID-19 Vaccine and Emphasizes Need for Equitable Global Access (Media Release).; 2020. Accessed June 10, 2021.
8. EMA. European Medicines Agency (EMA). Preparing guidance to tackle COVID-19 variants. EMA News. 10 February 2021. Published online February 10, 2021. Accessed June 10, 2021.
9. EMA. European Medicines Agency (EMA). COVID-19 vaccines. Overview 2021. Published online 2021. Accessed June 10, 2021. (Accessed November 6, 2021)
10. ECDC. Risk of SARS-CoV-2 Transmission from Newly-Infected Individuals with Documented Previous Infection or Vaccination.; 2021. (Accessed November 6, 2021)
11. Saciuk Y, Kertes J, Shamir Stein N, Ekka Zohar A. Effectiveness of a third dose of BNT162b2 mRNA vaccine [published online ahead of print, 2021 Nov 2]. J Infect Dis. 2021;jiab556. doi:10.1093/infdis/jiab556
12. Lamb YN. BNT162b2 mRNA COVID-19 Vaccine: First Approval. Drugs. 2021;81(4):495-501. doi:10.1007/s40265-021-01480-7
13. PFIZER. Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19 (Media Release). 2 Dec 2020. Lancet. 2021; 2021. Accessed June 10, 2021.
14. EMA. “Comirnaty EPAR”. European Medicines Agency (EMA). (Accessed November 6, 2021)
15. Karikó K, Muramatsu H, Welsh FA, et al. Incorporation of pseudouridine into mRNA yields superior nonim-munogenic vector with increased translational capacity and biological stability. Molecular Therapy. 2008;16(11). doi:10.1038/mt.2008.200
16. Walsh EE, Frenck RW, Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Can-didates. N Engl J Med. 2020;383(25). doi:10.1056/nejmoa2027906
17. Pardi N, Tuyishime S, Muramatsu H, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release. 2015;217:345-351. doi:10.1016/j.jconrel.2015.08.007
18. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/nejmoa2034577
19. Baden LR, el Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/nejmoa2035389
20. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021;384(15):1412-1423. doi:10.1056/nejmoa2101765
21. Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021; 397 (10286): 1725-1735. doi:10.1016/S0140-6736(21)00790-X
22. Hassan-Smith Z, Hanif W, Khunti K. Who should be prioritised for COVID-19 vaccines? Lancet. 2020;396(10264). doi:10.1016/S0140-6736(20)32224-8
23. ISS. Vaccine Day Il 27 Dicembre in Tutta Italia e in Europa ISS (Ministero Della Salute).; 2020. Accessed June 10, 2021.
24. Comunicato AIFA n. 620 - Autorizzato il vaccino BioNTech Pfizer. AIFA. Published online December 22, 2020.
25. Coggiola M, Cavallo R, Grillo E, et al. SARS-CoV-2 infection: Use and efficacy of antigen swab for the health surveillance of healthcare workers. Med Lav 2021; 112 (6): xxx-xxx
26. Ran L, Chen X, Wang Y, Wu W, Zhang L, Tan X. Risk Factors of Healthcare Workers With Coronavirus Disease 2019: A Retrospective Cohort Study in a Designated Hospital of Wuhan in China. Clin Infect Dis. 2020;71(16):2218-2221. doi:10.1093/cid/ciaa287
27. Shah ASV, Wood R, Gribben C, et al. Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: Nationwide linkage cohort study. The BMJ. 2020;371. doi:10.1136/bmj.m3582
28. Istituto Superiore di Sanità. Impatto della vaccinazione COVID-19 sul rischio di infezione da SARS-CoV-2 e successivo ricovero e decesso in Italia (27.12.2020 - 03.05.2021).
29. Keehner J, Horton LE, Pfeffer MA, et al. SARS-CoV-2 Infection after Vaccination in Health Care Workers in Cal-ifornia. N Engl J Med. 2021;384(18):1774-1775. doi:10.1056/NEJMc2101927
30. More on SARS-CoV-2 Infection after Vaccination in Health Care Workers. N Engl J Med. Published online 2021. doi:10.1056/nejmc2106004
31. Angel Y, Spitzer A, Henig O, et al. Association between Vaccination with BNT162b2 and Incidence of Sympto-matic and Asymptomatic SARS-CoV-2 Infections among Health Care Workers. JAMA. Published online 2021. doi:10.1001/jama.2021.7152
32. Thompson MG, Burgess JL, Naleway AL, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Re-sponders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(13):495-500. Published 2021 Apr 2. doi:10.15585/mmwr.mm7013e3
33. Fabiani M, Ramigni M, Gobbetto V, Mateo-Urdiales A, Pezzotti P, Piovesan C. Effectiveness of the comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021. Eurosurveillance. 2021;26(17):1-7. doi:10.2807/1560-7917.ES.2021.26.17.2100420
34. Amit S, Beni SA, Biber A, Grinberg A, Leshem E, Regev-Yochay G. Postvaccination COVID-19 among Healthcare Workers, Israel. Emerg Infect Dis. 2021;27(4):1220-1222. doi:10.3201/eid2704.210016